Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com

StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research note published on Wednesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Stock Down 5.6 %

CYCC opened at $1.51 on Wednesday. Cyclacel Pharmaceuticals has a fifty-two week low of $1.41 and a fifty-two week high of $13.20. The company has a fifty day moving average of $2.26 and a two-hundred day moving average of $3.81.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its quarterly earnings data on Tuesday, March 19th. The biotechnology company reported ($6.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($6.35) by $0.12. The firm had revenue of $0.03 million during the quarter. Sell-side analysts predict that Cyclacel Pharmaceuticals will post -18.7 earnings per share for the current fiscal year.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.